Arcutis Biotherapeutics, Inc.: insider trades · United States · SEC (Form 4)

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a U.S.-based biopharmaceutical company listed on NASDAQ in the United States, focused on medical dermatology and immunodermatology. The company’s investment case is highly concentrated: it develops and commercializes treatments for chronic inflammatory skin diseases, with an emphasis on differentiated topical therapies that aim to improve efficacy, safety, tolerability, and ease of use versus more cumbersome or steroid-based alternatives. Arcutis was founded in 2016 as Arcutis, Inc., and its headquarters are in Westlake Village, California, where the company houses its corporate and operational functions. ([arcutis.com](https://www.arcutis.com/arcutis-inc-founded-to-address-gap-in-immuno-dermatology-drug-development/?utm_source=openai)) The core commercial asset is ZORYVE (roflumilast), a topical, selective PDE4 inhibitor available in multiple formulations and indications. Arcutis has built its strategy around a dermatology franchise spanning plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. In 2025, the company secured FDA approval for ZORYVE cream 0.05% in children ages 2 to 5 with mild to moderate atopic dermatitis and subsequently launched the product in the U.S. It also continued to pursue label expansion in pediatric psoriasis and to generate long-term clinical data supporting the product’s profile across common inflammatory dermatoses. ([investors.arcutis.com](https://investors.arcutis.com/news-releases/news-release-details/fda-approves-arcutis-zoryver-roflumilast-cream-005-treatment?utm_source=openai)) Competitively, Arcutis operates in a niche but attractive segment of prescription dermatology, where clinical differentiation, convenience, chronic-use tolerability, and physician adoption are central to market share gains. The company positions itself as a specialist rather than a broad-based biotech platform, with deep dermatology expertise and a development engine tailored to validated inflammatory pathways. That specialization can be a strength, especially if ZORYVE continues to expand across age groups and indications, but it also leaves the business more dependent on a single branded franchise than larger diversified peers. ([arcutis.com](https://www.arcutis.com/about/?utm_source=openai)) Geographically, Arcutis remains primarily U.S.-centric, though it has begun building a broader North American footprint through Canada. Recent financial updates indicate strong product-revenue momentum through 2025 and into early 2026, reflecting accelerating commercial execution behind the ZORYVE franchise. Major recent catalysts include pediatric label expansion, new launches, ongoing publication of clinical and long-term safety data, and a continuing regulatory calendar in 2026 for additional potential expansions. For investors, Arcutis represents a commercial-stage specialty pharma story with meaningful growth potential, but one that remains exposed to regulatory timing, reimbursement dynamics, and the execution risks inherent in a focused dermatology portfolio. ([arcutis.com](https://www.arcutis.com/arcutis-announces-first-quarter-2026-financial-results-and-provides-business-update/?utm_source=openai))